University of Alberta
Edmonton, Alberta, T6G2G3, Canada
NCT Number: NCT05889494
The goal of this pilot trial is to test a protocol for a planned Canada-wide clinical trial looking at whether or not the use of a patients own blood works as good as the current standard of care using donated blood products to reduce blood loss in adult patients having heart surgery.
The main questions this study aims to answer are:
* Is the protocol practical, effective, and efficient. * Does the use of a patients own blood lower the following: bleeding, the amount donated blood products given, and complications.
Participants will be separated into two groups by a process that is like flipping a coin. One group will donate blood to themselves in the operating room and get their own blood back after surgery. The other group will be given blood products donated by other humans to treat the bleeding after heart surgery.
Researchers will compare both groups to see if patients that get their own blood have fewer donated blood products given at time of heart surgery and have less complications after surgery.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Not applicable
Edmonton, Alberta, T6G2G3, Canada
Cardiac surgery patients are at risk for perioperative bleeding and transfusion due to the invasiveness of the surgery and an acquired coagulopathy that is unique to this sub-specialty. High transfusion rates in this population are related to surgical field blood loss and the development of a multi-factorial coagulopathy. Due to these circumstances, cardiac surgery patients account for up to 20% of total annual blood transfusion with a subset of high risk patients consuming 80% of all transfusion in this group. On this basis, employing blood conservation methods is extremely relevant as the use of donated blood products leads to greater rates of infectious complications, atrial fibrillation, prolonged postoperative ventilation, acute renal injury, and reduced short and long-term survival in cardiac surgery patients. Reducing the health and cost burden associated with transfusion is an important outcome to both the patient and health care system. Intraoperative autologous whole blood transfusion, a blood-conservation method similar to acute normovolemic hemodilution, may reduce transfusion and its associated complications but there is a paucity of large scale prospective randomized control trials investigating its efficacy in the era of modern surgical approaches, targeted transfusion using point-of-care viscoelastic testing, and advanced perfusion techniques. The intent of this study is to assess the feasibility of a trial protocol for a large-scale national study investigating high volume autologous whole blood transfusion for reduction in allogenic transfusion, derivative administration, and transfusion-associated morbidity and mortality.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intraoperative high volume autologous whole blood withdrawal with re-transfusion following weaning from CPB.
Other names: Intraoperative autologous whole blood donation
Therapeutic treatment of CPB-induced coagulopathy using donated allogenic blood products including plasma, platelets, and cryoprecipitate and/or derivative administration using prothrombin complex and fibrinogen concentrates.
Time frame: 12 months.
Proportion of screened eligible patients that are successfully recruited.
Time frame: 24 hours
Number of units of red blood cell, plasma, platelets, cryoprecipitate administered intra-operatively and within the first 24hrs post-operatively.
Time frame: 24hrs
Dose (in units per kilogram) of prothrombin complex concentrates given intraoperatively and within the first 24 hrs postoperatively.
Time frame: 24 hrs
Dose (grams per kilogram) of fibrinogen given intraoperatively and within the first 24 hrs postoperatively.
Time frame: 24 hours
Measured in millilitres during first 24 hours post-operatively.
Time frame: 30 days
Measured in hours from time of arrival to ICU admission (index admission) until extubated.
Time frame: 30 days
Measured as number of days in ICU.
Time frame: 30 days
Measured as number of days in hospital.
Time frame: 30 days
As measured by laboratory serum troponin and one or more of: new left bundle branch block, new pathological Q waves on electrocardiogram, new regional wall motion abnormality on echocardiogram, identification of intracoronary thrombus on angiography or at the time of autopsy.
Time frame: 30 days
Any new infection following cardiac surgery and within the first 30 days post-operatively.
Time frame: 30 days
Defined as any acute onset focal neurological deficit lasting more than 24 hours that corresponded to clinical assessment and brain imaging.
Time frame: 30 days
Defined as any acute inflammation in the lung that causes disruption of the lung endothelial and epithelial barriers with partial pressure of oxygen tension in arterial blood (PaO2) to fraction inspired oxygen (FiO2) ratio of less than 300.
Time frame: 30 days
Defined per the Kidney Disease Improving Global Outcomes (KDIGO ) criteria for Stage 2 and 3 AKI: 2.0-2.9 time postoperative increase in serum creatinine from preoperative value (stage 2); greater than 3.0 times increase in serum creatinine from preoperative value or increase in serum creatinine to greater than or equal to 353.6 micromole per litre or initiation of new renal replacement therapy postoperatively (stage 3) within 30 days.
Time frame: 30 days
Defined as any new postoperative requirement of renal replacement therapy within the first 30 days of surgery.
Time frame: 30 days
Defined as new postoperative atrial fibrillation, persistent or paroxysmal, within the first 30 days postoperative.
Time frame: 30 days
Defined as death within the first 30 days postoperative.
Time frame: 12 months
Assess time required of research assistant to enroll participant and extract data variables from electronic medical record.
Time frame: 12 months
Assess proportion of recruited participants that are successfully randomized with (target of >80%).
Time frame: 12 months
Assess number of participants with inadvertent unblinding of the intensive care clinicians (target of <5%).
Time frame: 12 months
Assess number and define areas of protocol deviations.
Time frame: 12 months
Assess number of participants lost to follow-up (target <10%).
University of Alberta
Other
Autologous Whole Blood Management for Reduction of Blood Product Transfusion in Adult Cardiac Surgery Patients: a Local Feasibility/Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07475169
Body Weight, Hemorrhage
Cairo, Egypt
View Trial DetailsNCT05994989
Hemorrhage, Pathologic Processes
Diyarbakır, Turkey (Türkiye)
View Trial DetailsNCT04725305
Hemorrhage, Neurologic Manifestations
Houston, Texas, United States
View Trial DetailsNCT06238739
Body Temperature Changes, Hemorrhage
Bogotá, Colombia
View Trial Details